Payment overview · 2025
General Payments
$220,954.56
192 reported records · 21 companies
Healthcare provider profile · identity verified
Evan Scott Shlofmitz, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ROSLYN, NY · NPI 1639494479
Verified facts
What the public records show
CMS Open Payments records show Evan Scott Shlofmitz, DO received $220,954.56 in general payments during 2025 across 192 reported records.
Novo Nordisk Inc accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66,614.37 | 30.1% | 35 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $40,766.01 | 18.4% | 24 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35,627.91 | 16.1% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29,149.91 | 13.2% | 30 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $25,439.76 | 11.5% | 15 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $11,263.18 | 5.1% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$5,403.39 | 2.5% | 12 | 2025 |
| Gentuity, LLC | Unresolved — no canonical attribution shown | $2,490.37 | 1.1% | 3 | 2025 |
| SpectraWAVE, Inc | Unresolved — no canonical attribution shown | $1,750.00 | 0.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,414.58 | 0.6% | 19 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $283.62 | 0.1% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $202.84 | 0.1% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $159.85 | 0.1% | 8 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $123.59 | 0.1% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $118.47 | 0.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.68 | 0.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.63 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.41 | 0.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.22 | 0.0% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $18.00 | 0.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.77 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $145,019.19 | 43 |
| Consulting Fee | $55,296.88 | 17 |
| Food and Beverage | $7,233.01 | 107 |
| Travel and Lodging | $7,073.06 | 22 |
| Honoraria | $3,500.00 | 1 |
| Long term medical supply or device loan | $2,282.42 | 1 |
| Compensation for serving as faculty or as a speaker for a medical education program | $550.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66,571.06 | 33 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $40,766.01 | 24 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $34,054.69 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28,430.96 | 28 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $25,439.76 | 15 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $7,547.00 | 3 | 2025 |
Source payment records
|
|||||
| US EQ Undivided Normalized: us eq undivided |
Device | Philips North America LLC | $3,500.00 | 1 | 2025 |
Source payment records
|
|||||
| Gentuity HF-OCT Imaging System Normalized: gentuity hf oct imaging system |
Device | Gentuity, LLC | $2,490.37 | 3 | 2025 |
Source payment records
|
|||||
| Vis-Rx Prime Normalized: vis rx prime |
Device | Gentuity, LLC | $2,282.42 | 1 | 2025 |
Source payment records
|
|||||
| HyperVue Imaging System Normalized: hypervue imaging system |
Device | SpectraWAVE, Inc | $1,750.00 | 2 | 2025 |
Source payment records
|
|||||
| Starlight Imaging Catheter Normalized: starlight imaging catheter |
Device | SpectraWAVE, Inc | $1,750.00 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $1,291.99 | 8 | 2025 |
Source payment records
|
|||||
| X1-FFR Normalized: x1 ffr |
Device | SpectraWAVE, Inc | $750.00 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $701.67 | 9 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $550.00 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $397.29 | 6 | 2025 |
Source payment records
|
|||||
| Vis-Rx Normalized: vis rx |
Device | Gentuity, LLC | $207.95 | 2 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $148.43 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $141.25 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $139.98 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $127.58 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $127.58 | 1 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $123.59 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $118.47 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $83.27 | 5 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 5F VCS Normalized: cardiva vascade 5f vcs |
Device | CARDIVA MEDICAL, INC. | $69.08 | 2 | 2025 |
Source payment records
|
|||||
| INeb Devices Normalized: ineb devices |
Device | Philips North America LLC | $67.75 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $59.72 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $56.17 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| NHancer Rx Normalized: nhancer rx |
Device | BIOTRONIK INC. | $43.02 | 1 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| HEARTRAIL Normalized: heartrail |
Device | Terumo Medical Corporation | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $11.07 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $7.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 102 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 318 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 79 |
| Prasugrel Hcl | Prasugrel Hcl | 161 | 57 |
| Repatha Sureclick | Evolocumab | 150 | 26 |
| Losartan Potassium | Losartan Potassium | 134 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 51 |
| Xarelto | Rivaroxaban | 110 | 32 |
| Eliquis | Apixaban | 102 | 31 |
| Farxiga | Dapagliflozin Propanediol | 80 | 25 |
| Ozempic | Semaglutide | 68 | 14 |
| Ezetimibe | Ezetimibe | 67 | 28 |
| Jardiance | Empagliflozin | 65 | 17 |
| Furosemide | Furosemide | 64 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 26 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Lisinopril | Lisinopril | 43 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 16 |
| Ramipril | Ramipril | 40 | 12 |
| Brilinta | Ticagrelor | 35 | 15 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | 11 |
| Carvedilol | Carvedilol | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220,954.56 · 192 records | Novo Nordisk Inc | AVVIGO Guidance System, Acticor 7 VR-T DX, Ambulatory Monitoring & Diagnostics Undivided, BIOMONITOR, CARDIVA VASCADE 5F VCS, CARDIVA VASCADE 6/7F VCS, CARDIVA VASCADE MVP VVCS 6-12F, CVI Systems, DRAGONFLY OPSTAR, ELIQUIS, FFRct, General - Therapies, General - Vascular Access, Gentuity HF-OCT Imaging System, HEARTRAIL, HyperVue Imaging System, IGT Devices Undivided, INeb Devices, JOURNAVX, Kerendia, NEXLETOL, NHancer Rx, OPTIS, Ozempic, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, Paradise Ultrasound Renal Denervation System, REPATHA, ROTAPRO, Rybelsus, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Starlight Imaging Catheter, ULTREON, US EQ Undivided, Vis-Rx, Vis-Rx Prime, Wegovy, X1-FFR, XIENCE SKYPOINT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error